ClinicalTrials.gg
CompletedNCT02175186DAPTALBISUpdated Mar 22, 2023

Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

A Phase 4 interventional study of ALBIS and Placebo in Gastritis and Gastroduodenal Ulcer, sponsored by Young-Hak Kim, MD, PhD. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-03-22.

Sponsored by Young-Hak Kim, MD, PhD · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.

Enrollment
21st of 25
47 · median 242
Started
2015
the only one that year
Phase 4
5 of 32
none open now
Registered
8th of 32
by date

Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 21st largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2015, is one of 5 in phase 4, and was the 8th registered.

Gastritis

136 studies on the registry are indexed under Gastritis; 24 are open to participants now.

Browse Gastritis studies →

Open to participants now

3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gastritis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate effectiveness of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention.

03

Conditions studied

  • Gastritis
  • Gastroduodenal Ulcer

Keywords

  • Gastritis
  • Gastroduodenal Ulcer
  • Percutaneous Coronary Revascularization
  • Dual Antiplatelet Therapy
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 and 80 years
  • Patients undergoing percutaneous coronary intervention and need to take dual antiplatelet therapy continuously at least 12weeks
  • Modified Lanza Score grade 0-1 measured by upper gastrointestinal endoscopy
  • mild gastrointestinal symptom
  • Creatinen in blood ≤ 3mg/dl
  • BUN ≤ 50mg/dl
  • Birilubin ≤ 3mg/dl
  • and ALT ≤ 80U/L

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding
  • History of Stomach or esophagus surgery
  • Peptic ulcer or reflux esophagitis
  • Zollinger-Ellison syndrome or primary esophageal motility disorders
  • Malignant tumor
  • Bleeding tendency or coagulopathy
  • of ALBIS
  • Long term use of aspirin or P2Y12 receptor antagonist within 1month
  • Patients who tool medicine such as PPI, APA,H2blocker, Muscarine receptor antagonist, anti-gastic agent, antacid, anticaogulant, Bisphosphonate agents, Cytotoxic drug, NSAID, adrenal cortex hormone agents (topical treatment is allowed)
  • Terminal patient
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    ALBIS

    Albis Tab 2 tab twice a day 12weeks

    Drug: ALBIS

  • Placebo comparator
    Placebo

    placebo Tab 2 tab twice a day 12weeks

    Drug: Placebo

Interventions

  • DrugALBIS
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Incidence of gastric ulcer

    defined as a mucosal break of at least 5 mm in diameter(measured by gastrointestinal endoscopy) with depth, at 12weeks

    Time frame: 12weeks

Secondary outcomes

  1. Incidence of gastritis

    defined as Modified Lanza Score(MLS) grade 2\~4(measured by gastrointestinal endoscopy)at 12weeks

    Time frame: 12weeks

  2. The Endoscopic improvement rate of hemorrhage

    defined as Modified Lanza Score(MLS) grade

    Time frame: 12weeks

  3. The Endoscopic improvement rate of subjective symptom

    Time frame: 12weeks

  4. Total amount of antacid used during study period

    Time frame: 12weeks

07

Study locations

1 site
  • Asan Medical Center
    Seoul, Songpa-Gu, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Dec 2018, 46 months.

Of 14 phase 4 interventional studies under Gastritis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 26, 2014
StartActual
Jan 21, 2015
Primary completionActual
Dec 1, 2018
CompletionActual
Jan 8, 2019
Last update
Mar 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02175186
Lead sponsor
Young-Hak Kim, MD, PhD
Responsible party
Young-Hak Kim, MD, PhD (MD,PhD, Asan Medical Center) — Sponsor-investigator
First posted
Jun 26, 2014
Start date
Jan 21, 2015
Primary completion
Dec 1, 2018
Completion
Jan 8, 2019
Last update
Mar 22, 2023

Study contacts

Young-Hak Kim, MD
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion